comprehensive -WSS

comprehensive

author：leisure time 2025-08-04 03:43:15 - browse：1872

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Prescription digital therapeutics are key to pharma’s future

knowledge

WSS

Dexcom's push to bring CGM to type 2 diabetes patients

Living organ donors deserve priority status for transplants

Being 'nonadherent' patient made me a more empathetic doctor

The biotech scorecard for Q3: 15 stock

Hubble vs. James Webb telescope images: See the difference

Dexcom's push to bring CGM to type 2 diabetes patients

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Novo pauses ads for weight loss drug Wegovy amid demand

Sports medicine is finally prioritizing gender equality

Drug cartel violence flares in western Mexico after vigilante leader's killing

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

DIEP, the 'gold standard' of breast reconstruction, is under threat

Skip the lead apron during X

Continuity nursing helped my family in our darkest PICU moments

Can medical device makers keep up in the race to treat obesity?

Wikipedia

The wait for US passports is creating travel purgatory and snarling summer plans

Altering the blood type of lungs raises potential for universal organs for transplants

FDA approves first new drug developed for postpartum depression

Lupron, used to halt puberty in children, may cause lasting health problems

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Novo: Oral version of Ozempic leads to 15% weight loss

leisure time

hotspot

knowledge

focus